Literature DB >> 8420515

Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. VA Multiple Sclerosis Rehabilitation Study Group.

D N Bourdette1, A V Prochazka, W Mitchell, P Licari, J Burks.   

Abstract

We retrospectively determined health care costs among veterans with multiple sclerosis (MS) and correlated the costs with neurologic dysfunction. Total health care costs for the 165 patients averaged $35,000/year. VA benefits and homecare together accounted for 85% of the total costs. Total health care costs correlated with two measures of neurologic dysfunction, the Expanded Disability Status Scale (EDSS) (r = 0.61, p < 0.001) and the Incapacity Status Scale (ISS) (r = 0.64, p < 0.001). The costs of VA benefits, homecare, and hospitalizations also correlated with the EDSS, ISS, and other measures of neurologic dysfunction whereas the cost of outpatient clinic visits did not. In a period of three years, there were 40 hospitalizations, at a total cost of $412,800, that were potentially preventable with appropriate outpatient management. Improving selfcare and avoiding preventable hospitalizations might lower the considerable health care costs of MS.

Entities:  

Mesh:

Year:  1993        PMID: 8420515

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  22 in total

Review 1.  Outcomes assessment of drug treatment in multiple sclerosis clinical trials.

Authors:  M Malone; B Lomaestro
Journal:  Pharmacoeconomics       Date:  1996-03       Impact factor: 4.981

2.  Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.

Authors:  Bianca Weinstock-Guttman; Steven L Galetta; Gavin Giovannoni; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Paul W O'Connor; J Theodore Phillips; Chris Polman; William H Stuart; Frances Lynn; Christophe Hotermans
Journal:  J Neurol       Date:  2011-10-19       Impact factor: 4.849

3.  The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.

Authors:  Jasmina I Ivanova; Howard G Birnbaum; Seth Samuels; Matthew Davis; Amy L Phillips; Dennis Meletiche
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

4.  Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium)

Authors:  H Carton; R Loos; J Pacolet; K Versieck; R Vlietinck
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-04       Impact factor: 10.154

Review 5.  The economics of multiple sclerosis. Distribution of costs and relationship to disease severity.

Authors:  A N Grudzinski; Z Hakim; E R Cox; J L Bootman
Journal:  Pharmacoeconomics       Date:  1999-03       Impact factor: 4.981

Review 6.  Multiple sclerosis: it epidemiological, genetic, and health care impact.

Authors:  R Williams; A S Rigby; M Airey; M Robinson; H Ford
Journal:  J Epidemiol Community Health       Date:  1995-12       Impact factor: 3.710

Review 7.  Pharmacoeconomic considerations in the treatment of multiple sclerosis.

Authors:  Jessica Sharac; Paul McCrone; Ramon Sabes-Figuera
Journal:  Drugs       Date:  2010-09-10       Impact factor: 9.546

8.  Prescribing recommendations for interferon-Beta in multiple sclerosis.

Authors:  B Weinstock-Guttman; R A Rudick
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

9.  Prevalence and impact of pain in multiple sclerosis: physical and psychologic contributors.

Authors:  Adam T Hirsh; Aaron P Turner; Dawn M Ehde; Jodie K Haselkorn
Journal:  Arch Phys Med Rehabil       Date:  2009-04       Impact factor: 3.966

10.  Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents.

Authors:  Pierluigi Russo; Alessandro Capone; Andrea Paolillo; Francesco Macchia; Federica Ranzato; Gianfranco Costantino; Luca Degli sposti; Luciano Caprino
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.